Regenxbio : RGNX

RGNX

Stock Data

$9.07

$1.27 (16.28%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Regenxbio Inc is a pioneering biotechnology firm focused on developing gene therapies for genetic defects. Leveraging its NAV Technology Platform, the company is advancing a diverse pipeline of treatments targeting serious conditions like wet age-related macular degeneration, diabetic retinopathy, Duchenne muscular dystrophy, and various mucopolysaccharidoses. With a commitment to innovation, Regenxbio also collaborates with industry partners, including a significant agreement with AbbVie for international development. Founded in 2008 and based in Rockville, Maryland, Regenxbio is at the forefront of gene therapy research and development.